BGM Group (BGM) Competitors $7.29 -0.21 (-2.80%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BGM vs. MOR, AMRX, XENE, NAMS, HCM, CRNX, RARE, IMVT, ALVO, and KYMRShould you be buying BGM Group stock or one of its competitors? The main competitors of BGM Group include MorphoSys (MOR), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Alvotech (ALVO), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. BGM Group vs. Its Competitors MorphoSys AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals NewAmsterdam Pharma HUTCHMED Crinetics Pharmaceuticals Ultragenyx Pharmaceutical Immunovant Alvotech Kymera Therapeutics BGM Group (NASDAQ:BGM) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Do insiders & institutionals hold more shares of BGM or MOR? 18.4% of MorphoSys shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, BGM or MOR? BGM Group has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Does the media prefer BGM or MOR? In the previous week, BGM Group had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for BGM Group and 0 mentions for MorphoSys. BGM Group's average media sentiment score of 1.87 beat MorphoSys' score of 1.08 indicating that BGM Group is being referred to more favorably in the media. Company Overall Sentiment BGM Group Very Positive MorphoSys Positive Is BGM or MOR more profitable? BGM Group has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. BGM Group's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets BGM GroupN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Which has higher earnings & valuation, BGM or MOR? BGM Group has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBGM Group$26.85M26.72-$1.44MN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 SummaryBGM Group beats MorphoSys on 9 of the 11 factors compared between the two stocks. Get BGM Group News Delivered to You Automatically Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BGM vs. The Competition Export to ExcelMetricBGM GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$723.33M$3.08B$5.57B$9.81BDividend YieldN/A2.27%4.62%4.12%P/E RatioN/A20.7329.8025.74Price / Sales26.72356.90460.01111.33Price / CashN/A42.0537.7558.93Price / Book1.017.608.496.01Net Income-$1.44M-$54.65M$3.25B$264.84M7 Day Performance-3.79%4.45%3.71%2.66%1 Month Performance-8.68%5.71%4.03%1.56%1 Year PerformanceN/A30.51%35.47%29.07% BGM Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BGMBGM GroupN/A$7.29-2.8%N/AN/A$708.75M$26.85M0.00298MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730AMRXAMNEAL PHARMACEUTICALS3.0327 of 5 stars$9.04+2.2%$11.60+28.4%+19.6%$2.83B$2.79B903.408,100News CoverageInsider TradeXENEXenon Pharmaceuticals1.9873 of 5 stars$35.75+4.8%$53.20+48.8%-2.9%$2.75B$9.43M-11.11210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionNAMSNewAmsterdam Pharma3.539 of 5 stars$24.51+0.6%$41.20+68.1%+49.6%$2.74B$45.56M-15.094Analyst RevisionHCMHUTCHMED3.1966 of 5 stars$15.43-0.3%$28.00+81.5%-21.2%$2.69B$630.20M0.001,811Positive NewsCRNXCrinetics Pharmaceuticals3.4323 of 5 stars$28.36+3.6%$68.86+142.8%-40.2%$2.67B$1.04M-6.90210News CoverageEarnings ReportAnalyst ForecastRAREUltragenyx Pharmaceutical4.4646 of 5 stars$27.59+0.7%$81.50+195.4%-44.1%$2.66B$560.23M-5.001,294Analyst RevisionIMVTImmunovant2.2798 of 5 stars$15.23+3.2%$35.00+129.8%-46.7%$2.61BN/A-5.57120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionALVOAlvotech3.3744 of 5 stars$8.60+0.9%$14.00+62.8%-17.0%$2.59B$491.98M23.231,032News CoverageShort Interest ↓KYMRKymera Therapeutics3.2866 of 5 stars$39.10+3.8%$59.11+51.2%-5.3%$2.54B$47.07M-12.59170News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies MOR Competitors AMRX Competitors XENE Competitors NAMS Competitors HCM Competitors CRNX Competitors RARE Competitors IMVT Competitors ALVO Competitors KYMR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BGM) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTesla is in troubleThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BGM Group Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BGM Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access